Longeveron Inc. (NASDAQ:LGVN) Long Term Investor Notice: Investigation of Potential Wrongdoing
An investigation on behalf of current long term investors in Longeveron Inc. (NASDAQ:LGVN) shares over possible breaches of fiduciary duty by certain officers and directors was announced and NASDAQ:LGVN stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWire) -- 12/17/2021 --An investigation on behalf of current long-term investors in shares of Longeveron Inc. (NASDAQ: LGVN) concerning potential breaches of fiduciary duties by certain directors and officers of Longeveron Inc. was announced.
Investors who are current long term investors in Longeveron Inc. (NASDAQ: LGVN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LGVN stocks follows a lawsuit filed against Longeveron Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: LGVN stocks, concerns whether certain Longeveron directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Southern District of Florida the plaintiff alleges on behalf of investors of Longeveron Inc. (NASDAQ: LGVN) who purchased or otherwise acquired Longeveron Inc. (NASDAQ: LGVN) Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's IPO and/or who purchased Longeveron Inc. (NASDAQ: LGVN) securities between February 12, 2021 and August 12, 2021, that the defendants violated Federal Securities Laws.
More specifically, the plaintiff claims that, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose between February 12, 2021 and August 12, 2021 that Lomecel-B was not as effective in treating aging frailty as Defendants had led investors to believe, that accordingly, Lomecel-B's clinical and commercial prospects with respect to aging frailty were overstated, and that as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.
Those who purchased shares of Longeveron Inc. (NASDAQ: LGVN) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Media Relations Contact
Michael Daniels
Shareholders Foundation
1-858-779-1554
https://www.shareholdersfoundation.com/
View this press release online at: http://rwire.com/1350690